Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drugs whose agreements from the national centralized procurement have expired, with 13 products proposed for selection in this round [1][2]. Group 1: Procurement Details - The company has submitted applications for the continuation procurement organized by Jiangsu, Henan, and Guangdong provinces [1]. - The proposed selected products include 12 that were previously selected in the first to eighth batches of national centralized procurement and one new product, Paricalcitol Injection [1]. - The sales revenue from these products is projected to be approximately 651.20 million yuan in 2024, accounting for 48.25% of the company's total revenue for that year [1]. Group 2: Impact on Revenue - For the period from January to September 2025, the expected sales revenue from these products is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [1]. - The procurement cycle will last until December 31, 2028, during which medical institutions will prioritize the selected drugs, ensuring the completion of agreed procurement volumes [2]. Group 3: Market Stability - The overall pricing of the procurement is expected to remain stable or decrease further, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a price decrease compared to original sales prices, the selection of 13 products allows the company to maintain its market share and enhance the accessibility of these drugs [2].

格隆汇2月11日丨煜邦电力(688597.SH)公布，公司股票自2026年1月16日至2026年2月11日，已满足连续 三十个交易日中有十五个交易日的收盘价不低于"煜邦转债"当期转股价格的130%(含130%)，即9.49元/ 股，已触发《北京煜邦电力技术股份有限公司向不特定对象发行可转换公司债券募集说明书》中规定的 有条件赎回条款。 未来六个月内(即2026年2月12日至2026年8月11日期间)，如"煜邦转债"再次触发有条件赎回条款，公司 均不行使提前赎回权。公司将以2026年8月12日(若非交易日则顺延)为首个交易日重新计算，若再次触 发"煜邦转债"的有条件赎回条款，届时公司董事会将再次召开会议决定是否行使"煜邦转债"有条件赎回 的权利。 公司于2026年2月11日召开第四届董事会第十七次会议，审议通过《关于不提前赎回"煜邦转债"的议 案》，决定本次不行使"煜邦转债"的提前赎回权，不提前赎回"煜邦转债"。 ...

报告期内，公司全面拥抱AI，以数智车辆诊断终端、智慧能源中枢为业务入口，持续为全球客户提供 智能化服务，驱动了业绩的快速增长。在数智车辆诊断领域，公司持续深化AI多模态语音大模型和 AIAgents应用，具备AI特性的新品获得客户高度认可，实现了业绩的快速增长，其中TPMS产品持续保 持高速增长。在智慧充电领域，公司持续深化从功率模块、液冷超充设备到智能运维及AI巡检的端到 端系统能力，夯实"数智能源充电大模型"以及系列Agents应用，推进能源、交通、停车场运营、酒店公 寓等多个全球行业顶级客户的项目交付。 格隆汇2月11日丨道通科技(688208.SH)公布2025年度业绩快报，公司2025年度实现营业收入48.38亿元， 同比增长23.04%；实现归属于母公司所有者的净利润9.35亿元，同比增长45.89%；实现归属于母公司所 有者的扣除非经常性损益的净利润8.8亿元，同比增长62.77%。 ...

Core Viewpoint - The collaboration between 博睿数据 (Borui Data) and 火山引擎 (Volcano Engine) is focused on enhancing application performance monitoring through the integration of third-party probes provided by Borui Data [1] Group 1: Business Collaboration - Volcano Engine currently allows monitoring data to be reported to its APMPlus server via third-party probes provided by Borui Data [1] - There are plans for further deepening cooperation in data collection and analysis between the two companies [1]

Group 1 - The company announced the expiration of the sixth board of directors' term and plans to hold an employee representative meeting on February 11, 2026, to elect the seventh board of directors' employee director [1] - Lin Changchun was elected as the employee director of the seventh board of directors through a democratic vote, with the term aligning with that of the seventh board [1]

格隆汇2月11日｜紫光股份公告，公司决定终止筹划发行H股股票并在香港联交所主板上市。公司本次 终止发行H股股票事项不会对公司的经营活动造成重大影响，敬请广大投资者注意投资风险。 ...

格隆汇2月11日丨安邦护卫(603373.SH)公布，公司近日收到公司非独立董事卢卫东先生提交的书面辞职 报告。卢卫东先生因岗位调动，申请辞去公司第二届董事会非独立董事、董事会法治与合规委员会委员 职务。 ...

格隆汇2月11日丨紫光股份(000938.SZ)公布，拟向特定对象发行A股股票募集资金总额不超过55.7亿元 （含本数），扣除发行费用后的净额投资于收购新华三6.98%股权、研发设备购置项目、偿还银行贷 款。 如何抓住黄金波段机会？聪明钱的选择，黄金+股票一键搞定>> ...

格隆汇2月11日丨紫光股份(000938.SZ)公布，根据公司战略发展规划等情况，本着维护股东利益、对股 东负责的原则，经公司审慎分析和论证，公司于2026年2月11日召开第九届董事会第二十次会议，审议 通过了《关于公司终止发行H股股票并于香港联合交易所有限公司主板上市的议案》，公司决定终止筹 划发行H股股票并在香港联交所主板上市。公司本次终止筹划H股股票事项属于股东会授权董事会全权 处理的授权范围，无需提交股东会审议。 ...

Core Viewpoint - Watson Bio (300142.SZ) has announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners, aiming for a target size of 1 billion yuan, with the company contributing 450 million yuan as a limited partner [1] Group 1: Investment Fund Details - The fund's target size is set at 1 billion yuan [1] - Watson Bio will invest 450 million yuan of its own funds as a limited partner [1] - The fund will focus on various investment areas including synthetic biology, life and health, biological agriculture, bioenergy, biomaterials, technology platform enterprises, and high-throughput equipment [1] Group 2: Investment Areas - Investment areas include synthetic biology such as enzyme preparations, amino acids, and probiotics [1] - Life and health investments will cover plant extracts, recombinant collagen, sweeteners, and protein drugs [1] - Biological agriculture will focus on feed protein, micro-ecological preparations, animal vaccines, and biological nitrogen fixation [1] - Bioenergy investments will include bioethanol and biodiesel [1] - Biomaterials will focus on PLA, PHA, and PDO [1] - The fund will also target technology platform enterprises like strain development and AI protein design [1] - High-throughput equipment investments will include microfluidic devices and gene sequencing equipment [1]